CurrentUnitedHealthcarePolicy 2025D0109H

Saphnelo (anifrolumab-fnia) — Coverage Criteria for Systemic Lupus Erythematosus

Defines UnitedHealthcare medical benefit coverage criteria for Saphnelo (anifrolumab-fnia) for treatment of moderate to severe systemic lupus erythematosus (SLE), including initial and continuation authorization requirements and exclusions. Applies to providers seeking coverage decisions under UnitedHealthcare plans.

Policy Summary

PayerUnitedHealthcare

PolicySaphnelo (anifrolumab-fnia) — Coverage Criteria for Systemic Lupus Erythematosus

Policy CodePolicy 2025D0109H

Change TypeMaterial change — prescriber requirement added

Effective Date07/01/2025

Next Review DateN/A

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a rheumatologist; authorizations may be granted up to 12 months when criteria are met.

SourceLink

POLICY UPDATE CHANGES

Prescribing requirement: must be prescribed by or in consultation with a rheumatologist for initial and continuation therapy.

Updated Benefit Considerations, Clinical Evidence, and References sections and archived previous policy version 2024D0109G.

12 monthsmax initial auth

J0491HCPCS

M32.*ICD-10

07/01/2025effective

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Saphnelo (anifrolumab-fnia)

Initial Therapy

Covered when ALL of the following are met:

Diagnosis of moderate to severe systemic lupus erythematosus without severe active central nervous system lupus or severe active lupus nephritis

Concurrent standard-of-care therapy: Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (e.g., antimalarials, corticosteroids, or immunosuppressants) that is not a biologic

Step therapy / Benlysta: Patient has a contraindication, intolerance, or failure to Belimumab (Benlysta); for Medicare reviews, refer to the CMS section

Medicare-specific step therapy may apply

No combination biologics: Patient is not receiving Saphnelo in combination with a biologic agent or Belimumab (Benlysta)

Use in combination is unproven/not medically necessary

Dosing: Saphnelo is dosed according to US Food and Drug Administration labeled dosing for SLE

Prescriber requirement: Prescribed by or in consultation with a rheumatologist

New prescriber specialty requirement

Authorization duration: Initial authorization is for no more than 12 months<= 12 months

Continuation Therapy

Covered when ALL of the following are met:

Prior receipt: Patient has previously received Saphnelo injection for intravenous infusion

Documentation of response: Documentation of positive clinical response to prior Saphnelo therapy

Exclusion of severe disease: Patient is without severe active central nervous system lupus or severe active lupus nephritis

Coverage for Saphnelo (anifrolumab-fnia) excludes patients with severe active lupus nephritis and severe active central nervous system (CNS) lupus. Requests for Saphnelo when either of these severe manifestations is present should be denied as outside the scope of the coverage criteria. In addition, Saphnelo must not be used in combination with other biologic agents; combination use with other biologics is explicitly excluded.

Saphnelo is considered unproven and not medically necessary for treatment of severe active lupus nephritis and severe active CNS lupus. It is also considered unproven and not medically necessary for use in combination with other biologic agents. Requests meeting any of these situations may be denied under the policy.

Coding and Diagnosis Codes

Applicable HCPCS CodesHCPCSCovered

J0491

Injection, anifrolumab-fnia, 1 mg.

Referenced Diagnosis CodesICD-10

M32.10	Systemic lupus erythematosus, organ or system involvement unspecified.
M32.11	Endocarditis in systemic lupus erythematosus.
M32.12	Pericarditis in systemic lupus erythematosus.
M32.13	Lung involvement in systemic lupus erythematosus.
M32.14	Glomerular disease in systemic lupus erythematosus.
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus.
M32.19	Other organ or system involvement in systemic lupus erythematosus.
M32.8	Other forms of systemic lupus erythematosus.
M32.9	Systemic lupus erythematosus, unspecified.

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for both initial and continuation therapy. Initial and continuation authorizations may be approved for up to 12 months when all coverage criteria are met. Include HCPCS J0491 on the request and ensure dosing follows the FDA‑labeled regimen for Saphnelo (anifrolumab‑fnia).

Initial and continuation authorization: up to 12 months
HCPCS: J0491 (Injection, anifrolumab‑fnia, 1 mg)

Step Therapy

Step Therapy / Failure of Benlysta

For initial therapy, the patient must have a contraindication, intolerance, or documented failure of Benlysta (belimumab) prior to starting Saphnelo. Prior or concurrent use of at least one standard‑of‑care non‑biologic treatment (e.g., antimalarials, corticosteroids, or immunosuppressants) is required. Step therapy exceptions (medical contraindication or intolerance) must be documented.

Step requirement: contraindication, intolerance, or failure of Benlysta documented

Background on Anifrolumab and Clinical Context

Anifrolumab (Saphnelo) is a monoclonal antibody targeting the type I interferon receptor and is indicated for moderate to severe systemic lupus erythematosus (SLE). Clinical development included randomized trials demonstrating improvements in composite SLE response measures and effects on flares and steroid tapering; however, the policy excludes use in patients with severe active lupus nephritis or severe active CNS lupus and does not support combination use with other biologics.

Definitions and Clinical Endpoints

BICLA / SRI responses — definitions

BICLA (BILAG-based Composite Lupus Assessment)Requires reduction in any moderate-to-severe baseline disease activity with no worsening in any of nine BILAG organ systems, no worsening on SLEDAI, no increase ≥0.3 in Physician Global Assessment, no discontinuation of trial intervention, and no use of protocol-restricted medications.

SRI (SLE Responder Index) general descriptionComposite responder index assessing improvement in overall SLE disease activity (e.g., SRI[4] used as primary end point in trials), often combined with sustained steroid reduction as a co‑requirement.

BICLA components summarizedReduction of moderate-to-severe baseline disease activity; no new or worsening disease in any BILAG organ domain; no meaningful worsening on SLEDAI or Physician Global Assessment; continued receipt of study treatment; no prohibited medication use.

SRI primary end point use in trialsUsed as the primary end point in phase IIb study (SRI[4] at week 24 with sustained oral corticosteroid reduction) to evaluate anifrolumab efficacy.

Clinical roleBoth BICLA and SRI are multi-domain composite endpoints used in anifrolumab trials to assess overall clinical response, flare reduction, and glucocorticoid tapering outcomes.

Policy Revision History

2025-09-01revisionLatest

Corrected formatting error in References section.

2025-07-01revision

Updated Benefit Considerations, Clinical Evidence, and References sections and archived previous policy version 2024D0109G.

Policy Summary

PayerUnitedHealthcare

PolicySaphnelo (anifrolumab-fnia) — Coverage Criteria for Systemic Lupus Erythematosus

Policy CodePolicy 2025D0109H

Change TypeMaterial change — prescriber requirement added

Effective Date07/01/2025

Next Review DateN/A

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a rheumatologist; authorizations may be granted up to 12 months when criteria are met.

SourceLink

On This Page

No combination biologics:

Patient is not receiving Saphnelo in combination with a biologic agent or Belimumab (Benlysta)

Use in combination is unproven/not medically necessary

Dosing: Saphnelo is dosed according to US Food and Drug Administration labeled dosing for SLE

Prescriber requirement: Prescribed by or in consultation with a rheumatologist

New prescriber specialty requirement

Authorization duration: Authorization is for no more than 12 months<= 12 months

Required background therapy: at least one non‑biologic (antimalarial, corticosteroid, or immunosuppressant)

Documentation Required

Required Clinical Documentation

Submit documentation to support medical necessity: diagnosis of moderate to severe systemic lupus erythematosus (SLE) without severe active CNS lupus or severe active lupus nephritis; evidence patient is receiving at least one standard‑of‑care non‑biologic for active SLE; for initial therapy, documentation of contraindication/intolerance/failure of Benlysta when applicable; documentation of positive clinical response for continuation requests; labs and clinical notes that demonstrate disease activity and treatment response; and prescriber specialty or consultation (prescribed by or in consultation with a rheumatologist).

Include diagnosis code(s) (e.g., M32.10, M32.9) and clinical rationale
Evidence of moderate to severe SLE and absence of severe active CNS lupus or severe active lupus nephritis
Documentation of current non‑biologic SLE therapy
For continuation: documentation of positive clinical response
Prescriber: rheumatologist or consultation note

Denial Risk

Exclusion-based Denial Triggers

Requests will be denied for Saphnelo when any of the following exclusion conditions are present: severe active lupus nephritis, severe active central nervous system (CNS) lupus, or when Saphnelo is requested in combination with other biologic agents (including concurrent use with Benlysta).

Combination therapy with other biologics (including Benlysta) — denial risk
Severe active lupus nephritis — not medically necessary
Severe active CNS lupus — not medically necessary